The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
The pharmaceutical world is shifting: China has surged past the US in early-stage drug research, with programs jumping over 600% since 2015. This rapid growth promises cheaper, innovative treatments like advanced obesity drugs potentially better than Ozempic—but raises questions on access and geopolitics for patients worldwide.
Popular drugs like semaglutide and tirzepatide are transforming weight loss for type 2 diabetes and obesity patients. But a new UNC study warns of hidden muscle loss that could impact strength and mobility. Here's what the research means for safe, healthy weight management.
Health Canada recently warned Canadians not to buy or use unauthorized injectable peptide drugs amid reports of adverse reactions. Yet CBC News effortlessly purchased three such products online from different sellers. Experts highlight serious risks and contrast them with regulated GLP-1 medications like Ozempic and Wegovy.
Peptides are surging in popularity among influencers and biohackers for everything from injury recovery to youthful skin, but the science lags far behind the hype. With FDA bans on key ones like BPC-157 and potential changes ahead, here's what you need to know about their evidence, safety, and gray-market realities.
Tapatío hot sauce, a Southern California favorite, is gaining traction among GLP-1 users battling taste loss from drugs like Ozempic and Wegovy. Private equity firm Highlander Partners acquired the brand to capitalize on this trend, as spicy heat invigorates dulled taste buds. Experts explain the science behind GLP-1 taste changes and offer hope for recovery.
Social media is spotlighting GLP-1 receptor agonist side effects that clinical trials overlooked, according to a new study in Nature Health. Researchers sifted through 410,198 Reddit posts on semaglutide and tirzepatide, finding 43.5% of users reporting issues like nausea and fatigue. These insights reveal patient concerns beyond traditional data.
Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.
While most people on GLP-1 medications like Wegovy experience significant weight loss, 10-15% are non-responders. Emerging research shows these drugs still improve liver health, reduce heart risks, and more—independent of weight changes. A new mouse study reveals why, challenging insurance requirements for weight loss thresholds.
